ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic sclerosis"

  • Abstract Number: L18 • ACR Convergence 2024

    CCL19+ Fibroblasts Orchestrate Fibrotic Microenvironment via CCL19-CCR7 Axis in Systemic Sclerosis

    Wei Guo1, Zhaohua Li2, Dan Xu2 and Rong Mu2, 1Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China, 2Peking University Third Hospital, Beijing, China

    Background/Purpose: Understanding the roles of diverse fibroblast subsets is of great importance in elucidating the pathogenesis of fibrosis in systemic sclerosis (SSc). However, how the…
  • Abstract Number: 0678 • ACR Convergence 2024

    Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually

    Oliver Distler1, Margarida Alves2, Gerrit Toenges3 and Anna-Maria Hoffmann-Vold4, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 2Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, 3Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 4Oslo University Hospital, Oslo, Norway

    Background/Purpose: There is no consensus on the frequency of monitoring of patients with autoimmune disease-related interstitial lung diseases (ILDs), but a frequency of 1 year…
  • Abstract Number: 0712 • ACR Convergence 2024

    Efficacy of Sacubitril/Valsartan in Patients with Systemic Sclerosis and Heart Failure: A Retrospective Analysis

    Nouran Eshak1, Mahmoud Abdelnabi2, Jaxon Quillen1, Michael Pham1, Joseph Hentz1 and Vivek Nagaraja1, 1Mayo Clinic Arizona, Scottsdale, AZ, 2Mayo Clinic Arizona, Phoenix, AZ

    Background/Purpose: Cardiac involvement in systemic sclerosis (SSc) is common, underdiagnosed, and manifests variably. Myocardial involvement can manifest as left heart failure with preserved or reduced…
  • Abstract Number: 0963 • ACR Convergence 2024

    Stratification According to Autoantibody Status in Systemic Sclerosis Reveals Distinct Molecular Signatures

    Bénédicte ROUVIERE1, Christelle Le dantec2, Eléonore Bettacchioli3, Lorenzo Beretta4, Céline Cao2, Christophe Jamin2, Jacques-Olivier Pers5, Nathan Foulquier2, Martin Kerick6, Javier Martin6, Marta Alarcon-Riquelme7, Claire de Moreuil8, Divi Cornec3 and Sophie Hillion2, and PRECISESADS Clinical Consortium, PRECISESADS Metabolomic Study Group, 1CHRU de Brest, LBAI. UMR 1227, University of Brest, Brest, France, 2LBAI. UMR 1227, University of Brest, Brest, France, 3Service de Rhumatologie, CHU de Brest, Brest, France, 4Scleroderma Unit, Fondazione IRCCS Ca' Granda, University of Milan, Milan, Italy, 5University of Brest, Brest, France, 6Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Spain, Granada, Spain, 7Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 8Service de médecine interne, CHU de Brest, Brest, France

    Background/Purpose: Systemic sclerosis is a heterogeneous disease, complicating its management. Its complexity and the insufficiency of clinical manifestations alone to delineate homogeneous patient groups further…
  • Abstract Number: 1570 • ACR Convergence 2024

    Deconvolution of the Lipidomic Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: Lipid Biomarker Features That Predict Disease Progression in Skin and Lung

    Sunhwa Kim1, Yingtao Bi2, Vishal Kakkar3, Rebecca Ross4 and Francesco Del Galdo3, 1AbbVie, South San Francisco, CA, 2Abbvie, Worcester, MA, 3University of Leeds, Leeds, United Kingdom, 4Medicine and Health, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous autoimmune disease with variable clinical presentations and progression rates. Accurate patient stratification is crucial for optimizing treatment strategies.…
  • Abstract Number: 1687 • ACR Convergence 2024

    IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases

    Ioannis Parodis1, Dionysis Nikolopoulos2, Julius Lindblom3, Denis Lagutkin3, Lorenzo Beretta4, Maria Orietta Borghi5, Janique Peyper6, Guillermo Barturen7, Per-Johan Jakobsson3, Marta Alarcon-Riquelme8, Natalia Sherina3 and Helena Idborg9, and PRECISESADS Clinical Consortium, 1Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, 2Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 3Karolinska Institutet, Stockholm, Sweden, 4Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, 5Università degli Studi di Milano Statale, Milano, Italy, 6Sengenics Corporation Pte Ltd, Singapore, Singapore, 7Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, 8Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 9Karolinska Institutet, Solna, Sweden

    Background/Purpose: Systemic lupus erythematosus (SLE) is characterised by the production of a multitude of autoantibodies (abs). The diagnosis of SLE is supported by the presence…
  • Abstract Number: 1829 • ACR Convergence 2024

    Genomic Analysis of Skin Biopsies Differentiates Major Anti-Nuclear Autoantibody Subsets in Limited Cutaneous Systemic Sclerosis

    Philip Yee1, Medha Kanitkar2, Kristina Clark3, Voon Ong1 and Christopher Denton4, 1University College London, London, England, United Kingdom, 2University College London, London, United Kingdom, 3University of Oxford, Oxford, United Kingdom, 4University College London, Northwood, United Kingdom

    Background/Purpose: Systemic sclerosis (SSc) displays significant heterogeneity. Those with limited cutaneous systemic sclerosis (lcSSc) experience significant systemic organ involvement similar to those with diffuse cutaneous…
  • Abstract Number: 2447 • ACR Convergence 2024

    Features of Anti-Fibrillarin Positive Systemic Sclerosis Patients and Ethnic Differences: A European Multicenter Cohort

    Roberto D'Alessandro1, Stefano Rodolfi2, Alix Calot1, Louis Bébéar3, Corrado Campochiaro4, Veronica Codullo5, Francesco Del Galdo6, Ivan Castellvi Barranco7, Elisabetta Zanatta8, Silvia Bellando Randone9, Goncalo Boleto10, Loic Raffray11, Emmanuel Chatelus12, Patrice Cacoub13, Alexandre Le Joncour13, Paolo Airò14, cristiana sieiro santos15, Alain Lescoat16, Jérôme Avouac17, Christopher Denton18 and Yannick Allanore19, 1Rheumatology Department, Cochin Hospital, Université Paris Cité, APHP, Paris, France, Paris, France, 2Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, UK, London, United Kingdom, 3Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France., Bordeaux, France, 4IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, 5Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, 6University of Leeds, Leeds, United Kingdom, 7Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 8Unit of Rheumatology, Padova University, Padova, Italy, 9Department of Experimental and Clinical Medicine University of Florence Division of Rheumatology Scleroderma Unit, Careggi Hospital Florence, Italy, Florence, Toscana, Italy, 10Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal., Lisbon, Portugal, 11CHU La Réunion - Competence center for autoimmune diseases, Internal Medicine, Saint-Denis, Reunion, 12Rheumatology department strasbourg, Strasbourg, France, 13Department of Internal Medicine and Clinical Immunology France, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Pitié Salpetrière, 75013 Paris, France, Paris, France, 14Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, 15Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, 16Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, Rennes, France, rennes, France, 17Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 18University College London, Northwood, United Kingdom, 19Rheumatology department, Université Paris Cité, Cochin Hospital of Paris; France, Paris, France

    Background/Purpose: Anti-fibrillarin (AFA) auto-antibodies are rarely found in Systemic Sclerosis (SSc). Beyond the ethnic association with a higher prevalence in patients of Black ethnicity, the…
  • Abstract Number: 2530 • ACR Convergence 2024

    Single-cell Multi-omics Analysis of Reactive Lymph Nodes, Affected Tissues, and Blood Reveals a Naive-like CD4+TRAIL+ T Cell Population That Differentially Directs Effector Anti-nuclear Antigen Reactive Responses in Patients with Sjogren’s Syndrome and Systemic Sclerosis

    Theodoros Ioannis Papadimitriou1, Prashant Singh2, Arjan van Caam3, Madelon Vonk4, Irene E. van der Horst-Bruinsma5, Peter van der kraan3, Erik Aarntzen6, Martijn Huijnen7, Hans Koenen8 and Rogier Thurlings1, 1Radboudumc, Department of Rheumatology, Nijmegen, Gelderland, Netherlands, 2Radboudumc, Department of Medical BioSciences, Nijmegen, Netherlands, 3Radboudumc, Department of Rheumatology, Nijmegen, Netherlands, 4Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, 6Radboudumc, Department of Medical Imaging, Nijmegen, Netherlands, 7Radboudumc, Department of Medical BioSciences, Nijmegen, Gelderland, Netherlands, 8Radboudumc, Department of Medical Immunology, Nijmegen, Gelderland, Netherlands

    Background/Purpose: Recognition of self-peptides by autoreactive CD4+ T-cells is central to the disruption of immune tolerance. Although systemic autoimmune diseases such as Sjogren’s syndrome (SjS)…
  • Abstract Number: 0680 • ACR Convergence 2024

    Clinical Correlates of Physical and Mental Health in Early Systemic Sclerosis: Data from the Collaborative National Quality and Efficacy (CONQUER) Registry

    Ashima Makol1, Isha Lamba2, Dinesh Khanna3, John VanBuren4, Angela Child4, Jessica Alvey4, Shervin Assassi5, Elana Bernstein6, Flavia Castelino7, Lorinda Chung8, Luke Evnin9, Tracy Frech10, Faye Hant11, Laura Hummers12, Kimberly Lakin13, Dorota Lebiedz-Odrobina14, Yiming Luo15, Jerry Molitor16, Duncan Moore17, Carrie Richardson18, Nora Sandorfi19, Ami Shah20, Ankoor Shah21, Brian Skaug5, Virginia Steen22, Elizabeth Volkmann23 and Jessica Gordon24, 1Mayo Clinic, Rochester, MN, Rochester, MN, 2New York Presbyterian Hospital/Weill Cornell Medical Centre, New York, NY, 3University of Michigan, Ann Arbor, MI, 4University of Utah, Salt Lake City, UT, 5UTHealth Houston Division of Rheumatology, Houston, TX, 6Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 7Massachusetts General Hospital, Boston, MA, 8Stanford University, Woodside, CA, 9Scleroderma Research Foundation, Brisbane, CA, 10Vanderbilt University Medical Center, Nashville, TN, 11Medical University of South Carolina, Charleston, SC, 12Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, 13Hospital for Special Surgery, New York, NY, 14University of Utah, Cottonwood Heights, UT, 15Columbia University, New York, NY, 16University of Minnesota, Minneapolis, MN, 17Northwestern Memorial Hospital, Chicago, IL, 18Northwestern University, Chicago, IL, 19University of Pennsylvania, Philadelphia, PA, 20Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 21Duke University, Durham, NC, 22Georgetown University School of Medicine, Washington, DC, 23University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles, 24Division of Rheumatology, Weill Cornell Medical College, New York, NY

    Background/Purpose: Early years of Systemic sclerosis (SSc) are typically the period of peak disease activity and associated with greater pain, fatigue, sleep disturbance, physical impairment,…
  • Abstract Number: 0781 • ACR Convergence 2024

    An Expanded Cytotoxic CD8 T Cell Population Regulated by CD155-CD226 in SSc-ILD

    Takanori Sasaki1, Ye Cao2, Kathryne Marks3, Richard Ainsworth4, Kim Taylor5, Nunzio Bottini4, Mehreen Elahee6, Mari Kamiya3, Edy Kim6, Francesco Boin4 and Deepak Rao7, 1Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Cedars-Sinai Medical Center, Los Angeles, CA, 5University of California, San Francisco, CA, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). We aimed to identify circulating immune cells associated…
  • Abstract Number: 0966 • ACR Convergence 2024

    CDDO-Me Attenuates Pro-fibrotic Activation in Macrophages and Fibroblasts in Systemic Sclerosis

    Heetaek Yang1, Chanhyuk Park2, Chen-Yu Wang3, Emily Morris4, Karen Liby5, Michael Whitfield6 and Patricia Pioli2, 1Dartmouth College, West Lebanon, NH, 2Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Dartmouth College, Lebanon, NH, 4Dartmouth College, Enfield, NH, 5Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, 6Geisel School of Medicine at Dartmouth, Hanover, NH

    Background/Purpose: Systemic Sclerosis (SSc) is characterized by dysfunctional immune activation, oxidative stress, and fibrosis. In prior work, we have shown that SSc macrophages (MØs) have…
  • Abstract Number: 1571 • ACR Convergence 2024

    Growth Differentiation Factor 15 Is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis

    Vishal Kakkar1, Sunhwa Kim2, Yingtao Bi3, Christopher Wasson1, Stefano Di Donato4, Rebecca Ross5, Marco Di Battista6, Enrico De Lorenzis7, Thierry Sornasse2 and Francesco Del Galdo1, 1University of Leeds, Leeds, United Kingdom, 2AbbVie, South San Francisco, CA, 3Abbvie, Worcester, MA, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 5Medicine and Health, University of Leeds, Leeds, United Kingdom, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Pisa, United Kingdom, 7Catholic University of the Sacred Heart, Roma, Rome, Italy

    Background/Purpose: In systemic sclerosis (SSc), interstitial lung disease (ILD) remains the leading cause of mortality. A decline in forced vital capacity (FVC) is considered a…
  • Abstract Number: 1690 • ACR Convergence 2024

    FAPI-PET/CT as a Predictor of Accelerated Lung Function Deterioration in Systemic Sclerosis Related Interstitial Lung Disease (ILD): Preliminary-interim Analysis from a Confirmatory Risk Factor Study

    Armin Atzinger1, Yixing Huang2, Koray Tascilar3, Nadine Bayerl4, Jörg Distler5, Katrin Staudt3, Havanur Kartalczik6, Cosimo Bruni7, Oliver Distler8, Anna-Maria Hoffmann-Vold9, Tobias Bäuerle4, Andrea Prenner10, Florian Putz2, Katharina Breininger11, Torsten Kuwert12, Bernhard Kainz11, Georg Schett13 and Christina Bergmann14, 1Department of Nuclear Medicine, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 2Department Radiation Therapy, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 3Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 4Department Radiology, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Erlangen, Germany, 5Universitätsklinikum Düsseldorf and Heinrich-Heine-Universität Düsseldorf, Duesseldorf, Germany, 6Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Frankfurt, Germany, 7University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 9Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 10Department Artificial Intelligence in Biomedical Engineering; FAU, Erlangen, Germany, 11Department Artificial Intelligence in Biomedical Engineering, Erlangen, Germany, 12Department Nuclear Medicine, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Erlangen, Germany, 13Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 14Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany

    Background/Purpose: 68Ga-FAPI-PET/CT is a novel imaging method monitoring in-vivo fibroblast activation. We recently described an association of 68Ga-FAPI-uptake with deterioration of Forced Vital capacity (FVC)…
  • Abstract Number: 1830 • ACR Convergence 2024

    Single-cell RNA Sequencing Profiling of Very Early-Stage Systemic Sclerosis Skin Reveals a Fibroblast Pro-inflammatory Gene Signature and Keratinocyte Dysregulation

    Lumeng Li1, Elena Pachera2, Rucsandra Dobrota3, Kristina Bürki1, Carina Mihai3, Muriel Elhai4, Laura Much1, Astrid Hofman1, Pietro Bearzi5, Sophie Wagner6, Sarah Lötscher7, Anna-Maria Hoffmann-Vold8 and Oliver Distler9, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2University Hospital Zurich, Zurich, Switzerland, 3University Hospital Zurich, University of Zurich, Zurich, Switzerland, 4University Hospital zurich, Zürich, Switzerland, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, 6University of Zurich, Schlieren, Switzerland, 7Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Zurich, Switzerland, 8Oslo University Hospital, Oslo, Norway, 9Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland

    Background/Purpose: The poor prognosis of patients with systemic sclerosis (SSc) underscores the need to prevent disease onset and irreversible organ damage. This study aims to…
  • 1
  • 2
  • 3
  • …
  • 46
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology